

## Outcomes of Tofacitinib Dose Reduction in Patients with Ulcerative Colitis in Stable Remission from the Randomised RIVETING Trial

Double-blinded, randomised, parallel-group trial. Exploring efficacy and safety of TOFA dose reduction to 5mg BD vs remaining on 10 mg BD in patients in stable remission on 10 mg BD.

**Primary endpoints:** modified Mayo score remission at month 6.

### Results:

- Remission at month 6: 77.1% of TOFA5 vs 90% TOFA10.
- Smaller differences were found between groups in patients with baseline endoscopic subscore 0 vs 1 and in patients without vs prior antiTNF failure.
- Adverse events and serious adverse events similar across groups.

### Conclusions:

Most patients in stable remission on 10 mg BID maintenance therapy maintained remission following dose de-escalation. For patients who dose de-escalated, those in deep endoscopic remission and those without prior TNFi failure were more likely to maintain remission. Safety findings were consistent with the established safety profile of tofacitinib




Figure 2. Efficacy endpoints at Month 6 by dose group [FAS, non-responder<sup>a</sup>]. [A] Proportion of patients in modified Mayo score remission [primary endpoint];

